U.S. FDA approves biosimilar version of cancer drug Avastin

September 14, 2017
(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.
Advertisement

Related Videos


KSWB -   ▶  01:53



TODAY’S TMJ4 -   ▶  01:09



MultiVu -   ▶  01:00


Recent related news

AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a...
10 hours ago • Newsmax

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing...
12 hours ago • Business Wire

OVERLAND PARK, Kan. (AP) — A Kansas doctor is facing a lawsuit that alleges he contributed to a woman’s 2014 fentanyl overdose death. The U.S. Food and Drug...
4 hours ago • Seattle Times

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of two strengths of a generic version...
7 hours ago • Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the...
1 week ago • Business Wire

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use in prostate cancer patients whose cancer...
6 days ago • Reuters

WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA)...
6 days ago • GlobeNewswire

AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from the FDA for use in lung cancer.
2 days ago • Newsmax

BUENA, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has...
6 days ago • GlobeNewswire

SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and...
4 days ago • GlobeNewswire

You might like